Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02722668 · ADVERSE EVENTS

Adverse events

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep · Source last updated 2025-07-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
6 months
Other-event reporting threshold
5%

Adverse event and/or serious adverse event recorded according to targeted reporting outlined in protocol. 1. Events requiring prompt reporting including, but not limited to unanticipated death of a locally enrolled subject(s); new or increased risk; any adverse event that require a change to the protocol or consent form or any protocol deviation that resulting in harm 2. graft failure by Day 42 post-transplant

Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
No Anti-thymocyte Globulin (ATG)

Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.

0 / 50 / 51 / 5
Anti-thymocyte Globulin (ATG)

Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.

0 / 100 / 102 / 10

Group identifiers: EG000: No Anti-thymocyte Globulin (ATG) · EG001: Anti-thymocyte Globulin (ATG)

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

      Complete source fields
      description
      Adverse event and/or serious adverse event recorded according to targeted reporting outlined in protocol. 1. Events requiring prompt reporting including, but not limited to unanticipated death of a locally enrolled subject(s); new or increased risk; any adverse event that require a change to the protocol or consent form or any protocol deviation that resulting in harm 2. graft failure by Day 42 post-transplant
      event Groups
      1. deaths Num Affected
        1
        deaths Num At Risk
        5
        description
        Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
        id
        EG000
        other Num Affected
        0
        other Num At Risk
        5
        serious Num Affected
        0
        serious Num At Risk
        5
        title
        No Anti-thymocyte Globulin (ATG)
      2. deaths Num Affected
        2
        deaths Num At Risk
        10
        description
        Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
        id
        EG001
        other Num Affected
        0
        other Num At Risk
        10
        serious Num Affected
        0
        serious Num At Risk
        10
        title
        Anti-thymocyte Globulin (ATG)
      frequency Threshold
      5
      time Frame
      6 months

      Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

      Preserved source evidence · Not medical advice